Journal of Cancer Prevention 2018; 23(1): 18-24
Published online March 30, 2018
© Korean Society of Cancer Prevention
Joon-yeop Yang1, Xiancai Zhong1, Su-Jung Kim1, Do-Hee Kim1, Hyun Soo Kim1, Jeong-Sang Lee2, Hye-Won Yum1, Jeewoo Lee1, Hye-Kyung Na3, and Young-Joon Surh1
1Tumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University, Seoul, Korea, 2Department of Functional Food and Biotechnology, College of Medical Science, Jeonju University, Jeonju, Korea, 3Department of Food Science and Biotechnology, College of Knowledge-based Services Engineering, Sungshin Women’s University, Seoul, Korea
Correspondence to :
Young-Joon Surh, Tumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea, Tel: +82-2-880-7845, Fax: +82-2-883-2906, E-mail: firstname.lastname@example.org, ORCID: Young-Joon Surh,
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Curcumin, a yellow ingredient of turmeric ( Murine colitis was induced by dextran sulfate sodium (DSS) which mimics inflammatory bowel disease. Curcumin or tetrahydrocurcumin was given orally (0.1 or 0.25 mmol/kg body weight daily) for 7 days before and together with DSS administration (3% in tap water). Collected colon tissue was used for histologic and biochemical analyses. Administration of curcumin significantly attenuated the severity of DSS-induced colitis and the activation of NF-κB and STAT3 as well as expression of COX-2 and inducible nitric oxide synthase. In contrast to curcumin, its non-electrophilic analogue, tetrahydrocurcumin has much weaker inhibitory effects. Intragastric administration of curcumin inhibited the experimentally induced murine colitis, which was associated with inhibition of pro-inflammatory signaling mediated by NF-κB and STAT3.
Curcumin, a yellow ingredient of turmeric (
Murine colitis was induced by dextran sulfate sodium (DSS) which mimics inflammatory bowel disease. Curcumin or tetrahydrocurcumin was given orally (0.1 or 0.25 mmol/kg body weight daily) for 7 days before and together with DSS administration (3% in tap water). Collected colon tissue was used for histologic and biochemical analyses.
Administration of curcumin significantly attenuated the severity of DSS-induced colitis and the activation of NF-κB and STAT3 as well as expression of COX-2 and inducible nitric oxide synthase. In contrast to curcumin, its non-electrophilic analogue, tetrahydrocurcumin has much weaker inhibitory effects.
Intragastric administration of curcumin inhibited the experimentally induced murine colitis, which was associated with inhibition of pro-inflammatory signaling mediated by NF-κB and STAT3.
Keywords: Curcumin, Dextran sulfate sodium-induced colitis, NF-κB, STAT3, Tetrahydrocurcumin
Chronic inflammation has been implicated in pathogenesis of a variety of human malignancies. For instance, inflammatory bowel diseases (IBDs), such as ulcerative colitis and Crohn’s disease, has been considered to contribute to human colorectal carcinogenesis (CRC).1 Dextran sulfate sodium (DSS)-induced mouse colitis mimics IBD, and has been widely used in evaluating the preventive and therapeutic potential of many anti-inflammatory agents. However, while DSS-induced colitis is necessary, it is not sufficient to induce CRC. Tanaka et al.2 developed a murine model of colitis-associated colon carcinogenesis, in which colonic tumors developed within 20 weeks by a single intraperitoneal injection of a genotoxic carcinogen azoxymethane, followed by 2.0% to 2.5% DSS in drinking water for seven consecutive days.
COX-2 has been known to play a pivotal role in pathogenesis of CRC.3 Thus, the intake of the selective COX-2 inhibitor celecoxib resulted in the reduction of polyps in patients with familial adenomatous polyposis.4 Another enzyme involved in inflammation and oxidative stress is inducible nitric oxide synthase (iNOS). iNOS, which is overexpressed in colon cancer of humans and rodents, catalyzes the oxidative deamination of L-arginine to produce NO.5 Elevated levels of NO generated by iNOS induce inflammation, gene mutation, tissue damage, and malignant transformation.6 iNOS is likely to stimulate COX-2 activities,7 and hence affects colon carcinogenesis.6 Thus, COX-2 and iNOS are potential targets for the chemoprevention of colon cancer.5 NF-κB is a key transcription factor that mediates inflammatory gene expression, as well as immune responses.8 The 5′-promoter region of genes encoding COX-2 and iNOS contains putative NF-κB binding sites. NF-κB is mediated by several external stimuli that increase mitogen-activated protein kinase activity.9
Alleviating chronic inflammation represents an important component of current chemoprevention strategy. Though some non-steroidal anti-inflammatory drugs have protective effects against IBD, there has been an increased risk of heart attack or stroke observed in people intaking selective COX-2 inhibitors for 18 months or more. Thus, attention has been focused on the nutritional manipulation of colitis, and possibly inflammation- associated CRC. Numerous phytochemicals present in our diet have been shown to possess anti-inflammatory activities.10 One of the well-known dietary chemopreventive agents is curcumin, a yellow ingredient of the Indian spice turmeric (
Curcumin was supplied from LKT Laboratories (St. Paul, MN, USA). Tetrahydrocurcumin was prepared by conventional catalytic hydrogenation of curcumin in the presence of palladium on carbon. DSS (molecular weight, 36,000–50,000) was obtained from ICN Biochemicals, Inc. (Aurora, OH, USA) and MP Biomedical Inc. (Solon, OH, USA). Rabbit polyclonal COX-2 antibody was purchased from Cayman Chemical Co. (Ann Arbor, MI, USA), and iNOS antibody from BD Bioscience (Franklin Lakes, NJ, USA). Primary antibody for β-catenin was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-rabbit and anti-mouse horseradish peroxidase-conjugated secondary antibodies were products of Zymed Laboratories (San Francisco, CA, USA). An oligonucleotide probe containing the NF-κB sequence in the mouse COX-2 promoter region was obtained from Bionics (Seoul, Korea). An oligonucleotide probes harboring the STAT3 consensus sequence was obtained from Santa Cruz Biotechnology.
Male ICR mice (5 weeks of age) supplied by Central Lab. Animal Inc. (Seoul, Korea) were housed in climate-controlled quarters (24ºC at 50% humidity) with a 12-h light/12-h dark cycle. Curcumin or tetrahydrocurcumin suspended in 0.05% carboxymethyl cellulose was given orally (0.1 or 0.25 mmol/kg body weight daily) for 7 days. Control animals were given vehicle in lieu of curcumin. After additional one week treatment, mice were given 3% DSS in a tap water. Control mice were given a tap water. During the period of DSS treatment, all mice were subjected to following examinations on daily basis: weight measurement, fecal occult blood, and stool consistency. Mice were sacrificed by cervical dislocation. After measuring the length of the colorectal part, it was cut longitudinally and fixed with 10% formalin before embedded in paraffin. Each section (4 μm) was stained with H&E.
Colon tissues were subjected to homogenization in ice-cold lysis buffer (150 mM NaCl, 0.5% Triton-X 100, 50 mM, Tris-HCl [pH 7.4], 20 mM ethylene glycol tetraacetic acid, 1 mM dithiothreitol [DTT], 1 mM Na3VO4 and protease inhibitor cocktail tablet), and kysis for 30 minutes at 0°C followed by centrifugation at 14,000 rpm for 15 minutes. Supernatant was collected, and the total protein concentration was quantified by using the BCA protein assay kit (Pierce, Rockford, IL, USA). Cell lysates (30–50 μg protein) were boiled in SDS sample buffer for 5 minutes before electrophoresis on 8% to 12% SDS-polyacrylamide gel. Separated proteins were transferred to PVDF membrane, and the blots were blocked with 5% fat-free dry milk PBS containing 0.1% Tween-20 (PBST) or 1% BSA in Tris-buffered saline containing 0.1% Tween 20 (TBST) for 1 hour at room temperature. After washing with PBST or TBST buffer, the membranes were incubated for 2 hours at room temperature with 1:4,000 dilutions of primary antibody for actin, for 12 hours at 4°C with 1:1,000 dilutions of primary antibody for COX-2 or for 2 to 3 days at 4°C with 1:700 dilutions of primary antibody for iNOS. Blots were washed three times with PBST or TBST at 10 minutes intervals followed by incubation with 1:5,000 dilution of respective horseradish peroxidase conjugated secondary antibodies (rabbit, goat, or mouse) for 1 hour and again washed in PBST or TBST for three times. The corresponding proteins were visualized using an ECL detection kit obtained from Amersham Pharmacia Biotech (Buckinghamshire, UK).
The collected colon tissues of mice were homogenized in hypotonic buffer A (10 mM HEPES [pH 7.8], 10 mM KCl, 2 mM MgCl2, 1 mM DTT, 0.1 mM ethylenediaminetetraacetic acid [EDTA], and 0.1 mM phenylmethylsulfonylfluoride [PMSF]). To the homogenate was added 10% Nonidet P-40 (NP-40) solution, and the mixture was then centrifuged for 2 minutes at 14,000 rpm. The precipitated nuclei were washed twice with buffer A plus 40 μL of 10% NP-40, centrifuged, resuspended in 200 μL of buffer C (50 mM HEPES [pH 7.8], 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM PMSF, 20% glycerol) and centrifuged for 5 minutes at 14,000 rpm. The supernatant containing nuclear proteins was collected and stored at −70°C for further use.
The electrophoretic mobility shift assay was conducted using a DNA-protein binding assay kit (Gibco BRL, Grand Island, NY, USA). In brief, the NF-κB oligonucleotide probe 5′-GAG GGG ATT CCC TTA-3′ and the STAT3 oligonucleotide probe 5′-GAT CCT TCT GGG AAT TCC TAG ATC-3′ were labeled with [γ-32P] ATP by T4 polynucleotide kinase and purified on a Nick column (Amersham Pharmacia Biotech, Little Chalfont, UK). The reaction was carried out in 25 μL of the mixture containing 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM DTT, 1 mM EDTA, 4% glycerol, and 0.1 mg/mL sonicated salmon sperm DNA], 10 μg of nuclear extracts, and 100,000 cpm. of [γ-32P]ATP-end labeled oligonucleotide. The reaction mixtures were incubated at room temperature for 50 min. After addition of 2 μL of 0.1% bromophenol blue, the samples were electrophoresised using 6% non-denaturing polyacrylamide gel at 150 V in a cold room for 2 hours. Finally, the gel was dried and exposed to X-ray film.
Results are expressed as the means ± SD. Data were analyzed by one-way ANOVA and Student’s
DSS treatment for one week caused the macroscopic symptoms of colitis, such as a decrease in body weight and colon length, rectal bleeding and diarrhea. Based on the severity of stool consistency and rectal bleeding, DSS-induced pathogenic conditions were scored from 0 to 4.22 The sum was given into a form of the disease activity index. Oral administration of curcumin at 0.25 mmol/kg significantly attenuated the body weight loss (Fig. 1A) and shortening of colon (Fig. 1B), loose stool, diarrhea, and occult rectal blood (Fig. 2A). Exposure to DSS in drinking water for seven days also resulted in marked inflammation of the colon as reflected by thickening of the mucosal wall (Fig. 2B). Histopathological examination of formalin-fixed and paraffin-embeded colon tissues revealed marked destruction of colonic crypts after DSS treatment, with a progressive demolition of the mucosal barrier. Treatment with curcumin ameliorated DSS-induced inflammatory damage of the colon, and restored the architecture of the mucosal layer (Fig. 2B).
NF-κB has been identified as a tumor promoter in inflammation-associated cancer.23 The activation of NF-κB partly contributes to the transactivation of various proinflammatory genes (e.g.,
Curcumin possesses a highly electrophilic α,β-unsaturated carbonyl moiety, which can react with free sulfhydryl groups of many cellular proteins.24 To examine whether this electrophilic moiety is important for the anti-inflammatory properties of curcumin, we compared its effects on the DSS-induced colitis, activation of NF-κB and and expression of proinflammatory enzymes, with those of the non-electrophilic analogue, tetrahydrocurcumin (Fig. 4A). As compared to curcumin, tetrahydrocurcumin exerted much lesser inhibitory effects on colitis (Fig. 4B) and NF-κB DNA binding (Fig. 5A), Another transcription factor involved in inflammation-associated carcinogenesis is STAT3. Curcumin inhibited DSS-induced DNA binding of STAT3 in mouse colon (Fig. 5B). DSS-induced expression of COX-2 and iNOS, two representative pro-inflammatory enzymes known to be regulated by NF-κB and STAT3 was also attenuated by curcumin administration (Fig. 5C).
Over the past few decades, there has been a remarkable progress in our understanding the pathogenesis, development and progression of cancer. However, we still do not have effective therapies that can selectively kill cancer cells. Like other human disorders, cancer is basically preventible. Recently, attention has focused on naturally occurring substances, especially derived from plants, capable of intervening in multi-stage carcinogenesis.25 A wide variety of dietary phytochemicals present in fruits, vegetables, and spices have been known to exert cancer preventive effects through multiple mechanisms.10,25,26
Curcumin is an ingredient of the Indian spice turmeric (
Besides NF-κB, STAT3 has been reported to be highly activated in patients with IBDs, such as ulcerative colitis and Crohn’s disease,31 as well as in DSS-induced colitis in mice.32 STAT3 plays a key role in colonic inflammation and colitis-associated cancer.33,34 During the colitis-associated tumorigenesis, the activation of STAT3 promotes cell proliferation and survival through upregulation of its target genes, including
Tetrahydrocurcumin, one of the metabolites of curcumin, is structurally distinct from curcumin, in that it lacks the α,β-unsaturated carbonyl group. The biological activities of this nonelectrophilic analog of curcumin have been extensively investigated, but the results are discordant. Some studies have demonstrated that tetrahydrocurcumin exerts more potent effects than does curcumin, while others report that both compounds have a similar potency.38 In our present study, tetrahydrocurcumin exhibited weaker inhibitory effects compared with curcumin on DSS-induced colitis, DNA binding activity of NF-κB and STAT3, and expression of COX-2 and iNOS. It appears that the relative potency of curcumin and tetrahydrocurcumin relies on the mode of their interactions with the target molecules. If the interaction is covalent in nature, curcumin is expected to be superior to tetrahydrocurcumin, as the latter compound is unable to act as a Michael reaction acceptor due to the lack of the electrophilic functionality. Otherwise, the response may vary depending on the dose, route of administration, duration of treatment, intracellular environment, especially redox status, etc.
Taken together, the above findings suggest that oral administration of curcumin provokes anti-inflammatory effects by inhibiting the activation of NF-κB and STAT3 and their target protein expression. Considering a close association between inflammation and cancer and the role of aberrantly overexpressed NF-κB and STAT3 in tumor promotion, the present study provides the molecular basis for the previously reported chemopreventive effects of curcumin on inflammation-associated carcinogenesis.
This work was supported by the Global Core Research Center (GCRC) grant (No. 2011-003-0001) from the National Research Foundation, Ministry of Education, Science and Technology, Korea.
No potential conflicts of interest were disclosed.
Joon-Yeop Yang, Xiancai Zhong, Hye-Won Yum, Hyung-Jun Lee, Joydeb Kumar Kundu, Hye-Kyung Na, and Young-Joon SurhJournal of Cancer Prevention 2013; 18(2): 186-191 https://doi.org/10.15430/JCP.2013.18.2.186
Su-Hyeong Kim, Eun-Ryeong Hahm, Krishna B. Singh, Shivendra V. SinghJournal of Cancer Prevention 2020; 25(1): 1-12 https://doi.org/10.15430/JCP.2020.25.1.1
Hye Hyeon Lee, Jin-Woo Jeong, Su Hyun Hong, Cheol Park, Byung Woo Kim, and Yung Hyun ChoiJournal of Cancer Prevention 2018; 23(3): 134-140 https://doi.org/10.15430/JCP.2018.23.3.134